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The diagnosis and management of the haematologic manifestations of lupus 
 
Abstract 
Haematological manifestations in systemic lupus erythematosus (SLE) are frequently 
observed. They are diverse and range from mild to severe.  Therefore, different 
treatment approaches are needed from simply keeping vigilant to significant 
immunosuppression. Most treatment evidence is based on case-reports or small 
retrospective studies, as few randomized controlled trials have been performed. The 
development of biological therapy has opened new possible ways to treat the most 
severe cases but further clinical trials are necessary.  
In this review we consider the most common and characteristic haematological 
manifestations of SLE patients, focusing on their pathogenesis and management. 
Highlights 
 Haematological manifestations are common in Systemic Lupus 
Erythematosus. 
 Some of them are part of the classification criteria. 
 They can be related to the disease, concomitant blood disorders or 
iatrogenic. 
 These manifestations have a wide range of severity, from mild to life 
threatening. 
 Biological therapy has shown promising results, but more studies are 
necessary. 
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1. Introduction. 
Haematological manifestations in systemic lupus erythematosus (SLE) are common 
and diverse. Their frequency varies in different populations[1]. These manifestations 
can be due to the disease itself, another concomitant disease or iatrogenic. 
Haemolytic anaemia, leukopaenia, lymphopaenia and thrombocytopaenia are 
incorporated into both the 1997 update of the 1982 American College of 
Rheumatology (ACR) [2] and the 2012 Systemic Lupus International Collaborating 
Clinics (SLICC) [3] classification criteria for SLE. 
Most of these manifestations are caused by increased peripheral destruction of 
blood cells associated with circulating autoantibodies. The major haematological 
manifestations of SLE are anaemia, leukopaenia, thrombocytopaenia, and the 
antiphospholipid syndrome (APS). The bone marrow (BM) may also be a target in SLE 
and features such as myelofibrosis, aplastic anaemia and pure red cell aplasia can 
also occur. In this review we will consider the pathogenesis and management of 
these specific manifestations.  
2. Red Blood Cell Associated Pathologies 
A summary of red blood cell associated pathologies in SLE patients is shown in table 
1. 
2.1. Anaemia 
Anaemia is frequent, affecting more than 50% of patients throughout the course of 
the disease [4, 5].  
Anaemia is defined as haemoglobin of less than 12 g/dl in women and 13.5 g/dl in 
men [6]. It can be both immune and non-immune mediated in SLE patients.   
2.1.1. Anaemia of Chronic Disease 
2.1.1.1. Introduction 
Anaemia of chronic disease (ACD) is the most common type of anaemia in SLE 
patients, responsible for about one third of the cases[7]. 
It usually presents as normocytic and normochromic anaemia, with normal or 
elevated serum ferritin levels and a normal BM.  
2.1.1.2. Pathogenesis 
The aetiology of ACD in SLE is still not fully understood but it seems to be related to 
changes in iron homeostasis, inadequate erythropoietin (EPO) response or activity 
and impaired erythropoiesis. A schematic explanation is presented in figure 1. 
Iron Homeostasis 
During inflammation, iron homeostasis is significantly affected, as hepcidin 
production is regulated by iron. Hepcidin is a hormone produced in the liver that 
prevents iron from entering into the plasma compartment, by inhibiting iron 
absorption in the duodenum and its release from hepatocytes and macrophages. It is 
tightly regulated by the levels of serum iron and its production increases when iron is 
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abundant, preventing further absorption and release from stores. Its production 
diminishes or ceases when iron is deficient [8]. It prevents iron efflux by interacting 
with ferroportin 1 at the cell surface, leading to internalization and degradation of 
ferroportin 1 protein [9]. 
Hepcidin production also seems to be regulated by inflammatory cytokines. IL-6 
induces the production of hepcidin and a consequent hypoferraemic state [10]. 
Similarly adding IL-6-neutralizing antibodies to hepatocyte cultures ablated hepcidin 
production. IL-6 levels were significantly higher in SLE patients with active 
haematological disease and in those patients with anaemia the mean levels of IL-6 
were significantly higher than in those patients without it [11]. The Signal Transducer 
and Activator of Transcription 3 (STAT3) binding site at position -64/-72 of the 
hepcidin promoter controls IL-6-dependent transcriptional activation and 
knockdown of STAT3 by RNAi reduces hepcidin mRNA expression, implying that 
stimuli which activate hepatic STAT3 may also enhance hepcidin expression[12]. 
Inflammatory immune regulators such as IFN-γ and lipopolysaccharides seem to 
increase monocytes iron acquisition, by stimulating divalent metal transporter 1 
(DMT-1) expression and to retain the metal within the cells by inhibiting ferroportin 
synthesis [13]. In contrast, pro-hepcidin levels do not seem to correlate with disease 
activity, cytokine levels or serum iron levels in SLE patients [14]. 
Other cytokines, including TNF-α, IFN-γ and IL-1, are part of iron homeostasis by 
reducing the concentration of transferrin receptor on cell surface and increasing 
ferritin synthesis[9]. 
Erythropoietin  
The pathogenesis of ACD in different autoimmune diseases is related to reduced EPO 
activity, due to reduced production and erythroid cells resistance. EPO is 
fundamental in maintaining an adequate haematocrit level in human blood and its 
concentration increases with a low haematocrit level and vice versa.  
Absolute EPO levels were reduced in SLE patients, even in those without anti-EPO 
antibodies, but its correlation with haemoglobin and haematocrit variations was 
maintained [15]. The average levels of EPO in patients with SLE and anaemia did not 
vary according to the aetiology of anaemia[7].  
Anti-EPO antibodies have been detected in SLE patients in some studies [7, 15] and 
were more common in ACD [7]. However, in patients with anti-EPO antibodies there 
was no correlation between EPO levels and haemoglobin or haematocrit [15]. In 
contrast, there is conflicting evidence about the relationship between anti-EPO 
antibodies and the severity of the anaemia. In some studies, the decrease in 
haemoglobin levels in patients with anti-EPO antibodies was not statistically 
significant [7] and the anaemia was not more pronounced in SLE patients with anti-
EPO antibodies (as the EPO levels were also extremely low in these patients there 
may be some interference in the measurement of EPO due to the antibodies)[15]. In 
another study of 92 patients with SLE, the prevalence of anti-EPO antibodies in 
patients with more severe anaemia (6 out of 21 patients had a Haemoglobin <10.0 
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g/dl) was statistically significantly higher when compared with patients without 
anaemia and its antibodies titres were also more elevated [5]. 
Anti-EPO antibodies might also reflect SLE disease activity as they are associated 
with lower serum complement (C3 and C4) and higher anti-dsDNA autoantibody 
levels[15]. European Consensus Lupus Activity Measurement (ECLAM) scores were 
statistically significantly higher in patients with anti-EPO antibodies compared to 
those without them [5]. 
Impaired erythropoiesis 
The mechanisms of impaired erythropoiesis depend on the inhibition of progenitor 
cells. Several mechanisms are involved, one consists of type I and II interferons 
inhibiting this proliferation and through caspase and ceramide-dependent pathways 
also induce apoptosis [16] 
Both the sera and IgG isolated from four active SLE patients also suppressed 
progenitor cell growth in vitro [17]. 
2.1.1.3. Clinical implications 
ACD is a normochromic and normocytic anaemia that is usually mild  (haemoglobin 9 
to 10 g/dl) to moderate (haemoglobin below 9 g/dl) [7]. The reticulocyte count, the 
serum concentration of iron and the transferrin saturation are low. In contrast, 
transferrin and ferritin levels are normal and the latter may be elevated, due to 
retention in the reticuloendothelial system [18]. 
As in the evaluation of any cytopaenia, a peripheral blood smear should be 
performed to distinguish between peripheral destruction in isolated cytopaenias and 
BM failure in pancytopaenia[19]. 
To distinguish ACD from iron-deficiency anaemia (IDA), the ferritin concentration 
level is widely used and if it is >20 μg/dl, IDA is unlikely. A BM biopsy might be 
performed but its diagnostic yield is low [7]. In another study levels >30 μg/l gave a 
positive predictive value of 92% [20]. Moreover, soluble transferrin receptor (sTfR) 
has been studied as a possible indicator of iron deficiency, without any connection to 
chronic disease and inflammation. Patients with ACD+IDA or IDA alone had 
significantly higher sTfR values [21]. An sTfR Index (sTfR/log ferritin index) above 2 is 
indicative of true iron deficiency in ACD, while a index below <1 suggests functional 
iron deficiency [16]. A differential diagnostic approach between ACD and IDA is 
shown in figure 2. 
A nutritional deficiency of iron, folate or vitamin B12 should be considered If the 
reticulocyte count is inadequate [7]. Measurement of haptoglobin and lactate 
dehydrogenase to screen for haemolysis and renal function tests should also be 
performed [16]. Assays to measure hepcidin are not widely available [22]. The 
evaluation of EPO is not fully established and is only of value when the haemoglobin 
level is below 10 g/dl [18]. 
2.1.1.4. Treatment 
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Treatment of the underlying disease is the main goal in SLE patients with ACD [18], 
but mild cases often do not warrant treatment. 
Treatment with an erythropoiesis-promoting agent might benefit patients who are 
symptomatic. The most widely used are epoetin α (recombinant human EPO) or 
darbepoetin α which also play a part in treating anaemia of chronic renal 
insufficiency [19]. 
Transfusions can be an option in the case of severe or life-threatening anaemia, 
especially if bleeding conditions are also involved [18]. Long-term transfusions are 
not recommended due to iron overload and sensitization to HLA antigens [18]. 
Iron supplementation is not recommended if ferritin level is normal or increased, 
due to possible adverse outcomes [18], especially in intravenous supplementation, 
as iron might be linked to atherosclerosis and has an anaphylactic risk [23]. 
Underlying deficiencies, such as folate or vitamin B12, should be corrected [16]. 
SLE patients with ACD have a significantly higher disease activity than patients with 
other types of anaemia, probably due to more frequent concomitant lupus nephritis 
[7]. Remission of ACD is rare and its recovery is especially slow in patients treated 
with immunosuppressives [7]. 
2.1.2. Iron deficiency anaemia 
 
2.1.2.1. Introduction and Pathogenesis 
IDA is common in SLE patients, affecting about one third of 132 patients with 
anaemia[7]. It is usually due to chronic gastrointestinal haemorrhage secondary to 
medication, notably nonsteroidal anti-inflammatory medications and 
glucocorticoids[24]. 
2.1.2.2. Clinical implications 
IDA patients should be screened for a source of bleeding [19]. It may coexist with 
ACD, leading to a diagnostic challenge, as the serum ferritin is positively influenced 
by iron loading and inflammation [16]. 
2.1.2.3. Treatment 
After a bleeding source has been excluded or identified and treated, patients may 
begin oral or intravenous iron supplementation [19]. Iron therapy is the first line 
treatment for patients with IDA or ACD+IDA [18]. However, oral iron 
supplementation can lead to inadequate iron absorption in patients with ACD, 
because iron transfer from enterocytes to the circulation is impaired [18]. 
There are few data about erythropoietic agents and their possible side effects on the 
course of the underlying disease, as they can interfere with cytokine cascades. If they 
are introduced, haemoglobin levels should be determined after four weeks of 
therapy and subsequently at approximately 4 weekly intervals. Iron should be 
administered simultaneously as there will be no haemoglobin increase if iron 
deficiency is not corrected [18]. 
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2.1.3. Autoimmune haemolytic anaemia (AIHA) 
 
2.1.3.1. Introduction 
Haemolytic anaemia with reticulocytosis is included in both the ACR and the SLICC 
classification criteria. Autoimmune haemolytic anaemia (AIHA) involves anti-red 
blood cell (RBC) antibodies which damage erythrocytes in either a complement-
dependent or independent manner [19]. AIHA may be the first manifestation of SLE 
and can appear several years before an SLE diagnosis is made[4]. In one study 27 out 
of 41 cases of SLE-related AIHA occurred at SLE onset[25]. 
AIHA can be either primary or secondary. Secondary AIHA is considered a 
manifestation or a complication of an underlying disorder when: there is an overt 
immunological link between them; the association of AIHA and the concomitant 
disease occurs more frequently than the disease itself and the correction of the 
concomitant disease reverses the AIHA [26]. 
Its prevalence varies, probably due to the different diagnostic criteria for AIHA. Ten 
patients out of a cohort of 305 SLE patients had severe haemolytic anaemia (defined 
by haemoglobin <8.0 g/dl, in the presence of a positive direct antiglobulin test (DAT), 
a raised reticulocyte count and haemoglobin reduction by 3.0 g/dl since the last 
evaluation) [27]. In another cohort of 533 SLE patients, haemolytic anaemia 
(haemoglobin decrease of 3g/dl, rise in conjugated bilirubin and a reticulocyte count 
>5%) was identified in 50 (8%) patients [28] and in a multi-ethnic cohort of 1251 of 
female SLE patients 76 patients (6%) had haemolytic anaemia [29]. 
2.1.3.2. Pathogenesis 
RBC antibodies in SLE are mainly warm-type IgG, but doubts about its antigen 
specificity remain. The type of antibody is identified, based on the optimal 
temperature of antigen-antibody reaction. Warm-acting-AIHA and cold-acting-AIHA 
are distinguished by the optimal temperature of antigen–antibody reactivity [30], 
the latter being usually mediated by IgM[31]. RBC coated with warm IgG undergo 
changes in their membranes as they pass through the spleen, resulting in 
spherocytes, which are removed by phagocytosis [31].  
There may be an association between haemolytic anaemia and anticardiolipin 
antibodies (ACA) [27]. ACA were also statistically significantly more common in SLE 
patients with AIHA than with IDA [7]. Even in idiopathic AIHA, IgG and IgM ACA are 
present in higher titres than in normal controls, irrespective of SLE, suggesting it 
might play a bigger part in RBC destruction [32]. Others have described an increase 
in ACA IgM levels in SLE patients with AIHA, but no difference in the level of ACA IgG 
between groups was found[33], while in a study with 41 SLE patients with AIHA IgG, 
but not IgM, ACA antibodies were associated with AIHA [25]. Antiphospholipid 
antibodies (aPL) in SLE patients were also related to complement activation and anti-
RBC activity, with the levels of aPL IgG correlating to hypocomplementaemia and 
immunoglobulin binding on RBC [34]. Complement levels (both C3 and C4) are also 
lower in AIHA [7].  
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In NZB mice, the RBC autoantigen for IgG autoantibodies was identified as Band 3 
protein, the RBC anion channel [35], but the autoantigen in humans has yet to be 
identified.  
There are conflicting data as to whether anti-dsDNA antibodies are associated with 
AIHA [7, 27]. 
A possible role for CD55 and CD59, glycosylphosphatidylinositol-anchored proteins 
with complement inhibitory properties, in AIHA has been postulated. The diminished 
expression of CD55 and, more importantly, CD59 in RBC from many SLE patients with 
AIHA (and in some patients with primary AIHA), showed no correlation with the 
presence of aPL in SLE sera. However, acquired deficiency of CD55 and CD59 was 
seen more consistently in AIHA secondary to SLE than in primary AIHA, probably due 
to multiple alterations of the immune system. It might play a part in facilitating cell 
destruction and cytopaenia [36]. Another study confirmed a decreased expression of 
CD59 in SLE patients with AIHA when compared with SLE patients without it, primary 
AIHA and normal controls, but CD55 was not significantly decreased in SLE patients 
with AIHA [37].  
2.1.3.3. Clinical implications 
Studies of 76 patients with haemolytic anaemia revealed that pericarditis, pleuritis, 
lupus nephritis and seizures were more common than in those without haemolytic 
anaemia [29]. Similarly, in another large cohort group (870 SLE patients), 
leukopaenia, thrombocytopaenia and anti-dsDNA levels were predominant in 
patients with AIHA[38]. Severe AIHA has also been associated with damage accrual 
[39]. 
In one cohort of 305 SLE patients, none of the 10 patients with AIHA died as a direct 
result of the haematological manifestation [27]. In AIHA, the median time necessary 
to correct the anaemia is 3 months, and it has a low recurrence rate [7]. 
2.1.3.4. Treatment 
AIHA therapy is mostly based in isolated case reports and a few retrospective 
studies. There is a lack of established definitions of treatment goals, especially when 
to switch to second-line therapies. There are few clinical trials of first-line 
treatments. Many of the available studies were conducted in idiopathic AIHA and 
their results extrapolated to SLE patients with AIHA [31]. 
Treatment options are varied, but one study showed oral prednisone (mean dose 
1mg/kg) was used as the first-line treatment in 50% of patients and high dose 
methylprednisolone (1.5mg/kg/day) in the other 50% [40]. Twenty five per cent of 
patients with primary AIHA require at least 2 types of therapy, 13% require 3 and 4% 
> 4 types [41].  
The treatment usually used is glucocorticoids as first line of treatment (prednisone 
up to 1 mg/kg/day) and the haemoglobin response usually takes up to 3 weeks, [31]. 
When a sustained response is achieved, the dosage should be slowly tapered, 
although the optimal rate has not been established. If a patient fails to respond 
(defined by lack of response after 3 weeks treatment), significant doses of oral 
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prednisolone (around 15 mg/day) plus second line therapy are likely to be required 
[31]. In these cases, both conventional immunosuppressive therapy and 
splenectomy can be used. The pros and cons of the various therapeutic options are 
shown in Table 2.  
New therapies 
There have been some case reports of new therapies or combinations in the 
management of patients with mostly primary AIHA. Rituximab (RTX), which binds the 
CD20 molecule present on many B cells, and alemtuzumab, a monoclonal antibody 
that binds to CD52, were used in 21 consecutive adult patients, 8 of whom had AIHA, 
and beneficial responses were observed in all patients. The median duration of 
complete remisison was 46 weeks and 3 of 8 patients with AIHA maintained 
complete remission at 33, 46, and 89 weeks. CD4+ T cells were still at low levels at 
week 24, whereas B and NK cells partially recovered to basal levels [42]. 
In a 29-year-old woman with warm IgM AIHA secondary to eosinophilic 
granulomatosis with polyangeiitis, eculizumab and RTX was successfully 
administered after treatment failure to 3 previous treatments. A single 
administration of eculizumab 600 mg IV, a humanized monoclonal antibody against 
terminal complement C5, lead to a 3 g/dl increase in haemoglobin levels, without 
further need to treatment or transfusion. Subsequently, RTX was successfully 
administered as maintenance therapy[43]. In 64-year-old female patient with AIHA, 
secondary diffuse large B-cell non-Hodgkin lymphoma, was given C1 esterase 
inhibitor (C1-INH) to enhance the efficacy of the RBC transfusion. This lead to 
attenuated complement deposition on RBCs and reduction in haemolysis rate. 
Therefore, the response to RBC transfusion was higher and more sustained over time 
[44]. 
2.1.4. Thrombotic microangiopathic haemolytic anaemia 
In 1952, the name thrombotic microangiopathic haemolytic anaemia (TMHA) was 
introduced by Symmers to describe a diverse clinical presentation with localized or 
diffuse microvascular thrombosis, thrombocytopaenia, microangiopathic haemolytic 
anaemia, but with a negative Coombs’ test. Simultaneously, patients could have 
fever, neurological symptoms, and kidney involvement. [45] 
Its physiopathology is not fully understood, but it might be associated with aPL and 
TMHA could be a manifestation of APS. In a review, 61% of patients were 
categorized as having primary APS, and TMHA was the first manifestation of the APS 
in 93% of them. Thus, aPL might be a part of the development of TMHA in patients 
either with or without SLE. [46] In another study with 15 patients with TMHA (out of 
114 SLE patients), the presence of anti-Sm and anti-RNP antibodies was associated 
with a higher incidence of TMHA[47].  
The differential diagnosis of TMHA in SLE patients is extensive and challenging, as it 
can be a presentation of malignant hypertension, APS, catastrophic APS (cAPS), TTP 
or even a SLE flare. TTP and malignant hypertension have consumptive 
thrombocytopaenia with TMHA, in contrast to the immune-mediated processes seen 
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in APS and SLE. [48] In a study, 15 out of 114 SLE patients had TMHA and all of whom 
had a negative DAT result, with mild thrombocytopaenia and anaemia [47]. 
Patients should be systematically screened for lupus anticoagulant and ACA due to 
the association between TMHA and APS [46]. 
Disease activity as assessed by the SLE Disease Activity Index (SLEDAI) score was 
increased in patients exhibiting features of TMHA.[47] 
Choosing the optimal treatment is complicated due to the difficult differential 
diagnosis and often therapy for all possible diagnoses is given simultaneously [48]. In 
one study 7 out of 15 patients responded to methylprednisolone alone, 4 responded 
to methylprednisolone with plasmapheresis, 2 to methylprednisolone and 
immunosuppressive therapy, and 2 methylprednisolone with both plasmapheresis 
and immunosuppressive therapy [47]. 
2.1.5. Pure red cell aplasia or hypoplastic anaemia 
Pure red cell aplasia (PRCA) is characterized by normochromic normocytic anaemia 
and reticulocytopaenia, with aplasia or severe hypoplasia of the red cell line, while 
leukocyte and megakaryocyte lines in the BM remain normal [49]. In most cases, 
PRCA is diagnosed concomitantly or shortly after SLE diagnosis [50]. 
The pathogenesis of PRCA is varied including genetic defects affecting the 
erythropoietic lineage, viral infections (such as parvovirus B19) and autoimmune-
related factors [49]. 
As previously described in ACD, anti-EPO antibodies can also lead to PRCA by 
neutralizing erythropoiesis [51]. It has also been shown that sera from SLE patients 
can suppress granulocytic and erythroid colony formation in vitro. The IgG fraction 
has been isolated from these sera and its action is probably related to binding CD34+ 
haematopoietic progenitor cells, but not to CD33+ cells [17]. However, in vivo 
reports are conflicting [52]. 
The disease responds to prednisone in the majority of cases, but tapering is difficult 
[50]. 
Aplastic anaemia is characterized by pancytopaenia with a low reticulocyte count 
and hypocellular BM. It is rare in SLE [53]. 
It is thought that antibodies to BM progenitor cells lead to BM aplasia and resultant 
pancytopaenia. This idea is supported by data showing that the suppression of 
colony forming units-granulocyte monocyte (CFU-GM) was mediated by the serum 
or IgG complement-dependent fraction of a SLE patient’s serum in the acute phase. 
In contrast the IgG fraction obtained six weeks after that acute phase showed no 
CFU-GM suppression[54]. Knowing that cytopaenias may occur on the basis of 
inhibited myelopoiesis in SLE flares should lead to ANA screening in patients with BM 
acellularity of unknown cause [55]. 
Some case reports describe the use of cyclosporine (CSA) (300 mg/day) [53] and CYC 
in refractory cases with remarkable success[56]. 
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2.1.6. Others 
SLE patients can obviously be affected by nutritional deficiency anaemia. Low serum 
vitamin B12 levels have been reported in SLE patients [57]. Few cases of SLE patients 
with pernicious anaemia have been described [58-60]. 
3. White Cell Associated Pathologies 
A summary of white cell associated pathologies in SLE patients can be found in table 
3. 
3.1. Leukopaenia 
In the 1997 update of the ACR criteria leukopaenia is defined as levels <4000/mm3 
on at least 2 occasions and lymphopaenia as levels <1500/mm3 on at least 2 
occasions [61]. Similarly, in the SLICC classification criteria, leukopaenia (<4000/mm3 
on at least one occasion) and lymphopaenia (<1000/mm3 at least once) are also part 
of the SLE classification criteria [3]. 
3.1.1. Neutropaenia 
Neutropaenia in autoimmune diseases can be either primary or secondary. 
Antineutrophil antibodies can induce neutropaenia, which may also result from 
peripheral sequestration, BM inhibition, or apoptosis. The specific target of the 
autoantibodies is unknown and it is quite common for these cases to develop 
thrombocytopaenia or haemolytic anaemia simultaneously [62]. 
In SLE patients, thrombocytopaenia, central nervous system involvement and 
immunosuppressive medications were identified as independent risk factors for 
developing neutropaenia and, in some cases, the BM showed signs of myeloid 
hyperplasia, suggesting that BM failure is not the cause of neutropaenia [63]. 
Another study linked severe neutropaenia with the presence of IgG on myelocytes 
and promyelocytes, as well as mature cells. Patients with moderate neutropaenia 
had IgG only on neutrophils and metamyelocytes whereas in the control group IgG 
did not deposit on peripheral blood or earlier precursors [64]. There was a significant 
decrease in the number of granulocytic precursors cells (CFU-C) in SLE patients. In 
neutropaenic patients the numbers of CFU-C were lower than in non-neutropaenic 
patients, suggesting that a decrease in BM CFU-C plays a part in neutropaenia in SLE. 
Simultaneously, T cells from SLE patients inhibited in vitro CFU-C colony formation in 
the BM from healthy individuals [65]. 
It is also likely that an autoimmune aetiology also contributes directly to 
neutropaenia in SLE patients. There is an inverse relationship between the 
neutrophil count and the ability of patients’ sera to opsonize granulocytes for 
recognition and clearance by human monocytes. The level of membrane-binding IgG 
significantly correlated with opsonic activity while the level of Clq-binding immune 
complexes was also elevated in some patients and correlated with opsonic 
activity[66]. Another study revealed that neutrophil count significantly correlates 
negatively with the C3-binding ability in patients with SLE [67]. These data suggest 
the possibility of complement activation, driven by antineutrophil antibodies.  
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In a study of 72 SLE patients, anti-Ro/SSA antibodies were linked to a lower average 
neutrophil count than those lacking these antibodies. The sera from the former 
bound neutrophils more than either sera from anti-Ro negative SLE patients or from 
healthy controls. It was also shown that anti-Ro antibody can fix complement on the 
surface of neutrophils, but its antigen was a 64-kD protein instead of 60-kD Ro[68]. 
In SLE patients with neutropaenia, the possibility of concomitant infection and 
medication side effects, particularly immunosuppressants must be considered [31, 
63]. BM aspiration and biopsy may be necessary in acute and severe cases[31]. 
Treating the underlying condition and close monitoring are sufficient in most 
patients. Neutropaenia is only treated specifically if it is severe with concomitant 
infection [30]. In these cases, there are some limited data regarding the possible 
benefit of human recombinant granulocyte colony stimulating factor (rhG-CSF). 
There is a case report of severe neutropaenia in SLE patient who was treated with 
rhG-CSF (100 pg/d, 5 days) together with methylprednisolone pulse therapy, with a 
good outcome [69]. There is also a small study of 9 SLE patients with refractory 
infection who received rhG-CSF without corticosteroids. The average PMN count 
increased in two days, but 3 patients had a haematological flare [70]. 
3.1.2. Lymphopaenia 
Out of 158 SLE patients with active disease studied from the time of diagnosis, 
lymphopaenia was present in 75%. After disease reactivation, another 18% also 
developed lymphopaenia[71]. 
Autoantibodies to lymphocytes seem to be part of the pathogenesis as titers of IgG 
antibodies to lymphocytes (but not IgM) have been shown to correlate inversely 
with lymphocyte and complement levels [72]. Another study reported that the 
sensitivity and specificity of IgG antilymphocyte antibodies in SLE was 42.3% and 
96.7%, respectively and the antibodies were independently associated with 
lymphopaenia [73]. In a study conducted in human T and B cell lines as antigens (P12 
(CD4-, CD8+), Jurkat (CD4-, CD8-), Hut78 (CD4+, CD8-) and Wa (B cell), respectively), 
serum antibody titres were higher than those in normal control subjects and it 
seems that autoantibodies react with both T and B cells [72]. The titers of anti-
Ro/SSA, anti-dsDNA and anti-ribosomal P were also more elevated in the 
lymphopaenic group. No correlation was found for anti-La/SSB, anti-RNP, anti-Sm or 
anti-histones [74]. 
Antibodies against galectin 8 (Gal-8) are highly specific as they do not cross-react 
with other galectins (multifunctional proteins which mediate cell contact, migration, 
growth and apoptosis), and they are also associated with lymphopaenia in SLE 
patients, notably in those with a malar rash. However, these antibodies are also 
present in rheumatoid arthritis and sepsis [75]. 
As far as peripheral T cells are concerned, a reduction in T cell numbers relates to the 
presence of anti-T cell antibodies especially in acutely ill patients. B cells numbers, 
measured through lymphocytes bearing surface Ig, also frequently correlate with 
disease activity[76]. In patients with different subtypes of lupus erythematosus, T-
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helper lymphocyte cells are more often diminished in patients with more severe 
presentations [77]. 
The CD55 and CD59 proteins have complement inhibitory properties. In SLE patients 
CD55 surface density was higher in CD19+ cells than in CD3+ cells, while CD 59 was 
higher in CD3+ cells. In SLE patients with lymphopaenia, CD55 and CD59 were less 
expressed in both CD3+ and CD19+ lymphocytes [74]. The surface expression of Fas 
antigen is also higher on both naïve and memory CD+ and CD8+ T cells from SLE 
patients, however only CD4+ cells levels have an inverse correlation with the 
expression of Fas antigen [78].  
CD27+ memory B cells seem to be the most common population in SLE, but in lower 
numbers than in healthy controls. After immunosuppressive therapy, CD27+ cells 
remain stable, while naïve CD27- B cells and CD27high plasma cells are diminished 
[79]. 
The relationship between disease activity, as measured by SLEDAI and 
lymphopaenia, has been studied. At the beginning of one study SLEDAI score 
correlated positively with lymphopaenia (84) and after 1 year, a high SLEDAI score 
was similarly associated with lymphopaenia. Nonetheless, after 2 years the SLEDAI 
score only correlated with anti-dsDNA antibodies. Lymphopaenia is, together with 
other haematological changes, a predictor of flare during the following year [80]. 
SLEDAI levels were significantly higher in SLE patiens with anti-lymphocytic 
antibodies [73]. 
As for neutropaenia, the underlying disease should be managed appropriately. 
Although controversial [81], prophylactic antibiotic therapy against Pneumocystis 
jiroveci might be considered in more severe cases of lymphopaenia and it seems to 
have a good safety profile [82]. 
3.2. Leukocytosis 
The major effect of glucocorticoids on neutrophils appears to be the inhibition of 
neutrophil adhesion to endothelial cells, which leads to neutrophilia [83]. Obviously, 
the main reason to an increased leukocyte count is infection, which requires swift 
action in terms of diagnosis and treatment. 
4. Platelet associated pathologies 
A summary of platelet associated pathologies in SLE patients can be found in table 4. 
4.1. Thrombocytopaenia 
4.1.1. Introduction  
Thrombocytopaenia is a frequent manifestation in SLE patients though it is often 
mild. Three different mechanisms are linked to thrombocytopaenia: impaired 
production in the BM, sequestration in the spleen and accelerated destruction [31]. 
The most common is immune mediated platelet destruction in the peripheral 
circulation by antiplatelet antibodies [84-86].  
4.1.2.  SLE immune Thrombocytopaenia 
4.1.2.1. Introduction 
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Immune thrombocytopaenia is an immune-mediated disorder occurring as a primary 
event (P-ITP) characterized by isolated thrombocytopaenia or associated with other 
conditions, such as SLE (SLE immune thrombocytopaenia) [87]. 
SLE immune thrombocytopaenia is a common clinical manifestation, ranging from 7 
to 30% [88-91], which is defined as a platelet count <100x109/mm3 without any 
other identifiable cause [2, 3, 61]. In a large single-centre cohort study 50 out of 632 
patients had thrombocytopaenia [92]. Of these 50 patients, 54% had platelet counts 
of 50 to 100 x109/mm3, 18% had counts between 20 and 50 x109/mm3, and 28% had 
a platelet count of less than 20x109/mm3.  
4.1.2.2. Pathogenesis 
Mechanisms implicated in immune SLE thrombocytopaenia are summarized in figure 
3. 
4.1.2.2.1. Antiplatelet Autontibodies 
Antiplatelet autoantibodies bind to platelets, leading to platelet phagocytosis in the 
spleen. This is often associated with a normal or increased number of 
megakaryocytes in the BM. These autoantibodies can be found in both P-ITP and SLE 
immune thrombocytopaenia, but immunological differences have been described 
between the two conditions [31] and even among SLE patients with immune 
thrombocytopaenia there are differences in the autoimmunity directed against 
platelets [93]. 
Antiplatelet autoantibodies are present up to 60% of SLE patients, the majority being 
IgG (60%) (23% are IgM) [94, 95]. In P-ITP, the antigens for antiplatelet antibodies 
are glycoprotein IIb/IIIa (GpIIb/IIIa) and membrane glycoprotein (αIIaβ3integrin), and 
they can also be seen in SLE patients. In addition, glycoprotein Ia/IIa (GpIa/IIa) and 
glycoprotein IbIX (GPIbIX) antigens have also been described in SLE immune 
thrombocytopaenia. The presence of antiplatelet antibodies does not automatically 
lead to the development of thrombocytopaenia. Other factors for 
thrombocytopaenia development in seropositive patients are active disease and 
complement activation [92]. 
4.1.2.2.2. Other causes of immune-related platelet destruction 
The role of antiphospholipid antibodies 
SLE patients with thrombocytopaenia are more often positive for lupus 
anticoagulant and higher levels of IgM ACA have been related to a potential role of 
aPL in its pathogenesis. López-Soto et al related ACA, antiphosphatidic, 
antiphosphoserine, antiphosphoinositol and lupus anticoagulant antibodies with 
thrombocytopaenia [96]. Moreover, the presence of ACA has been found to increase 
the relative risk for thrombocytopaenia four-fold [97]. Nevertheless, the exact 
pathophysiology of the relationship between the presence of aPL and 
thrombocytopaenia remains unknown. 
The role of antibodies against thrombopoietin and antibodies against 
thrombopoietin receptor 
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Although immune thrombocytopaenia is often related to a normal or increased 
number of megakaryocytes, amegakaryocytic hypoplasia has been described in a few 
cases [98-100]. This feature has been related to antibodies against thrombopoietin 
(TPO) and against the TPO receptor (c-mpl receptor). The binding of TPO (the c-mpl 
ligand) to its receptor is the key regulator of platelet production. SLE patients have 
higher serum levels of TPO, as well as autoantibodies against TPO and its receptor. 
Moreover, the presence of autoantibodies against the TPO receptor may be 
associated with a poorer response to steroids [86, 101, 102]. Despite these findings, 
the exact role of these antibodies in the pathogenesis of lupus thrombocytopaenia is 
uncertain.  
The role of genetics 
A genetic contribution to thrombocytopaenia was suggested in a study of 159 SLE co-
affected siblings, in which the risk of thrombocytopaenia was increased when 
compared with a cohort of 709 non-related SLE patients [103]. A genetic linkage 
genetic linkage at 1q22 and 11p13 was found and also correlated with a severe SLE 
form [104, 105]. However, it remains unclear whether these ﬁndings are directly 
related to the mechanism of thrombocytopaenia or a marker of severe SLE. 
4.1.2.3. Clinical Implications 
The presentation of immune thrombocytopaenia in SLE patients can be divided in 
three main forms: acute, chronic and prior P-ITP. An overview of these 
manifestations can be found in table 5. The acute form occurs as part of a 
generalised exacerbation of SLE. It is usually severe (platelet count <25x109/mm3) 
and may be associated with life-threatening haemorrhage risk. It often responds to 
steroid treatment and improves when the SLE comes under control.  The chronic 
form is more common and it rarely causes major symptoms. It is not related to 
disease activity.  Although it is less responsive to steroid therapy, this is not a major 
concern because the platelet count is usually modestly decreased (75-125x109/mm3) 
and it may not require speciﬁc therapy. P-ITP can precede SLE diagnosis in 3% to 16% 
of patients and may occur up to 10 years before SLE becomes clinically 
apparent[106].  
In most patients, thrombocytopaenia follows a benign course, platelet counts down 
to 30x109/mm3 rarely cause more than a prolonged bleeding time. However counts 
of less than 20x109/mm3 are usually associated with petechiae, purpura, ecchymosis, 
epistaxis and other clinical bleeding. Severe thrombocytopaenia is uncommon so 
major bleeding only occurs in a minority of patients. It can be fatal if it involves the 
central nervous system or the gastrointestinal tract [87].  
The presence of thrombocytopaenia is an important independent risk factor for 
mortality in SLE. This has been validated for many, though not all European, North 
ans South American, Hispanic, Chinese and African American patients with SLE [107, 
108]. SLE patients with late-onset thrombocytopaenia have a greater risk than those 
whose thrombocytopaenia occurred early in the course of their disease [94].  
SLE patients with thrombocytopaenia are also more likely to have significant organ 
damage, such as heart, kidney and central nervous system involvement [90, 92, 109-
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111]. Thrombocytopaenia has also been correlated with low levels of complement 
(C3), higher SLE disease activity, haemolytic anaemia and the presence of other 
cytopaenias [27, 92]. 
4.1.2.4. Treatment 
When treatment is required, the approach is similar to P-ITP. Immune 
thrombocytopaenia treatment is usually recommended for symptomatic patients 
with platelet counts <25x109/mm3 [112]. Platelet transfusions should be avoided in 
immune thrombocytopaenia and only considered when the platelet count is less 
than 10x109/mm3 or invasive procedures are needed [113]. 
Conventionally, high-dose glucocorticoids are considered first-line therapy in severe 
thrombocytopaenia [114, 115]. Hydroxychloroquine (HCQ) or danazol can be added 
in refractory patients or in an effort to taper glucocorticoids. If there is no significant 
improvement within three weeks or the side effects are intolerable, other 
immunosuppressive treatments should be considered [113], such as azathioprine 
(AZA), CSA, CYC, vincristine or vinblastine, but they have limited success [116]. 
Splenectomy used to be an alternative therapeutical option for SLE patients with 
refractory immune thrombocytopaenia [117-119]. However, in addition to concerns 
about high rate of infection [120] and the long-term outcome [119], the introduction 
of RTX has rendered this operation almost obsolete. RTX may be used in both SLE 
immune thrombocytopaenia and P-ITP. It is preferred to splenectomy in SLE 
patients, because its B lymphocyte depleting approach may be beneficial for other 
manifestations of SLE [121]. Moreover, a significant decrease of antiplatelet 
antibodies, especially IgG isotype, occurs after RTX treatment [122].  
In emergency situations several therapies are used simultaneously, such as high-
dose glucocorticoids and IVIg. IL-11 could be considered if the patient does not 
response adequately to the ﬁrst two choices. Plasmapheresis can be effective in 
patients with refractory thrombocytopaenia and active bleeding [123].  
 
Additional treatments such as other anti-other monoclonal therapies, including at 
CD40L, targeting co-stimulatory molecules (such as CTLA4-Ig) and immune 
complexes (such as intravenous anti-D) may be considered though there are few 
data. 
 
The main treatments available with their targets can be found in figure 4, and a 
summary of their indications in table 6. 
4.1.3. Thrombocytopaenic thrombotic purpura.  
4.1.3.1. Introduction 
TTP is a thrombotic microangiopathy first described in 1924 by Moskowitz. It is 
characterized by the pathological findings of platelet thrombi in the microcirculation 
of several organs. Patients with TTP typically develop microangiopathic haemolytic 
anaemia, thrombocytopaenia and organ failure of variable severity 
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Various clinical subtypes of TTP exist, including hereditary forms. TTP can be 
primary/idiopathic or secondary/acquired, associated with other conditions 
(autoimmune disorders, malignancies…) [124]. A number of autoimmune disorders 
have been reported in association with TTP and SLE is the most frequent 
autoimmune disease associated with TTP [125]. However, TTP is a rare complication 
in the context of SLE and generally occurs in patients with severe lupus activity and 
renal involvement [126]. The estimated incidence of TTP in SLE is 2 –3% [127]. 
However, post-mortem examination of patients suggest an even higher incidence 
[128]. 
4.1.3.2. Pathogenesis 
TTP can result from a severe deficiency in ADAMTS13 (a disintegrin and 
metalloprotease with ThromboSpondin type 1 repeats) [129] but additional genetic 
and/or environmental triggers are thought to be required to trigger acute illness. 
ADAMTS13 limits platelet aggregation by cleaving Von Willebrand factor (VWF) 
multimers into less adhesive forms. Its deficiency leads to persistence of ultra-large 
VWF (ULVWF) multimers, widespread formation of microvascular platelet thrombi, 
and subsequent microangiopathic haemolytic anaemia and organ ischaemia [130]. 
Severe ADAMTS13 deficiency in acquired TTP is caused by autoantibodies against 
ADAMTS13, which either neutralize ADAMTS13 activity or accelerate its clearance 
[131, 132]. High titres of anti-ADAMTS13 antibodies may be associated with 
refractory disease in SLE patients [133].  
Anti-nuclear (ANA), anti-Ro and anti-dsDNA antibodies may develop many years 
before the diagnosis of SLE [134]. This association has been also published in a TTP 
population, where anti-Ro and anti-dsDNA antibodies at the time of TTP diagnosis 
were significant risk factors for the later development of SLE [125]. This finding could 
lead to early identification of an associated autoimmune disease allowing early 
targeted management. 
The predisposing role of aPL in TTP is controversial and remains unclear [125, 135]. 
4.1.3.3. Clinical implications 
Prominent clinical features of TPP include severe thrombocytopaenia (<50x10 mm3), 
microangiopathic haemolytic anaemia, fever, renal failure and neurological 
dysfunction. There is considerable overlap between the characteristic features of 
TTP and some SLE features [136]. Although the diagnosis of SLE usually precedes that 
of TTP [137], it can develop simultaneously or after the diagnosis of TTP [126, 138-
142]. In paediatric populations, there are some data that suggest that primary TTP 
may evolve to SLE [143]. 
Prolonged follow-up is necessary after an acute primary TTP, especially when anti-Ro 
or anti-dsDNA antibodies are present at the time of TTP diagnosis [125]. 
TTP in SLE is often life-threatening and in spite of earlier and more aggressive 
therapy in SLE patients, the mortality is higher and the time to complete remission 
longer than in idiopathic TTP, suggesting a refractory and more severe disease [126, 
144]. 
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4.1.3.4. Treatment 
Plasmapheresis can successfully remove the autoantibodies and replenish 
ADAMTS13, thereby restoring functional ADAMTS13 levels. Since its introduction, 
mortality from TTP has decreased dramatically from 90% to 25% [145]. Hence, it is 
the first-line treatment in TTP [146, 147]. However, SLE patients seem more 
refractory to this treatment [126]. 
In case of a poor response to plasmapheresis in SLE patients with TTP, other 
treatments to be considered include high-dose glucocorticoid, CYC and IVIg [138, 
148].  
RTX has been successfully used in refractory TTP in SLE [136, 149-153]. Since TTP can 
precede SLE onset, it has been hypothesized that if RTX was used for the treatment 
of TTP this could prevent or delay the appearance of overt clinical SLE. However, the 
results of a cross-sectional study do not support this hypothesis since acute TTP 
patients previously treated with RTX did not have a lower incidence of autoimmune 
disorders than those not given the treatment [125]. 
4.1.4. Other causes of thrombocytopaenia in SLE patients 
Drug therapy used in SLE can induce thrombocytopaenia often by leading to 
impaired production of platelets in the BM. This is well recognized with drugs such as 
AZA and CYC and rarely with drugs such as HCQ, MMF and CSA. 
Platelet consumption may also occur in association with microangiopathic 
haemolytic anaemia. Pseudo-thrombocytopaenia, secondary to platelet aggregation 
or platelet adherence to leukocytes, must always be considered and excluded by 
examining the peripheral smear [31]. BM examination, especially in older patients, 
should also be considered to rule out occult myelodysplasia. 
4.2. Thrombocytosis. 
Platelet count >400x109/mm3 constitutes thrombocytosis. It is much less common 
than thrombocytopaenia in SLE. It may occur as a result of active disease or reactive 
to the underlying inflammatory process. Hyposplenism (or functional aesplenia or 
autosplenectomy) has been reported as a cause of thrombocytosis in SLE patients 
[154, 155] and may be related with aPL or with associated APS [156, 157]. 
5. Pancytopaenia. 
There are a number of potential causes of pancytopaenia in SLE patients, notably 
drugs, peripheral destruction, other concomitant diseases, autoimmune 
myelofibrosis and uncommon causes such as macrophage activation syndrome 
(MAS).  
However, when a SLE patient presents with a reduced number of red cells, 
leukocytes and platelets, this often suggests haematopoietic failure as the result of 
immune-mediated BM damage. When performing a BM biopsy in SLE patients with 
an unexplained pancytopaenia, hypocellularity was described as a predominant 
finding [158, 159]. 
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5.1. Autoimmune myelofibrosis and SLE. 
5.1.1. Introduction 
Myelofibrosis is rare and characterized by deposition of reticulin fibres in the BM 
stroma, which usually occurs in response to clonal proliferation of myeloid stem cells 
in myeloproliferative disorders [160]. It has been described in association with 
several haematologic malignancies and metastatic solid malignancies [161, 162]. 
However, it can be also a manifestation of endocrine or inflammatory conditions. 
The association between myelofibrosis and autoimmune disorders was first 
described in 1978 [163]. Twenty years later Paquette et al [164] proposed and 
defined the term autoimmune myelofibrosis. Since then, around 40 cases have been 
reported in association with SLE [165]. The spleen is often, but not always, enlarged. 
However, this pathology may be more common, with cases being incorrectly 
characterized as blood peripheral cytopaenias in patients previously diagnosed with 
SLE, and cases being misdiagnosed as primary myelofibrosis in patients not 
previously diagnosed with SLE [165]. 
5.1.2. Pathogenesis 
The aetiology of autoimmune myelofibrosis remains unknown.  One hypothesis 
proposes that circulating autoantibodies and immune complexes of SLE stimulate 
the megakaryocytes Fc-receptors, resulting in the release of growth factors.  
Platelet-derived growth factor, found in megakaryocytes and platelets, stimulates 
fibroblast growth [160]. Consequently, transforming growth factor β and epidermal 
growth factor promote collagen synthesis [166]. Fibroblast proliferation, increased 
collagen synthesis or altered collagen turnover lead to an increase in reticulin, which 
is deposited in BM stroma [167]. It has been suggested that autoantibodies against 
CD34+ and cytotoxic T cells act as causal agents in BM damage and also perpetuate 
damage [168].  
5.1.3. Clinical implications 
Autoimmune myelofibrosis can be diagnosed at the time or after the diagnosis of 
SLE. Most patients present with either bicytopaenia (anaemia and 
thrombocytopaenia) or pancytopaenia [165]. It is more frequent in younger patients 
than primary myelofibrosis (median age 29 years vs 66 years in primary 
myelofibrosis) [30, 165, 169]. The majority of case reports are among Caucasian or 
Mexican-American, followed by African-American and Arab patients [30, 165]. 
BM biopsy in patients with suspected immune SLE myelofibrosis is virtually 
indistinguishable from primary myelofibrosis [167]. The biopsy of immune SLE 
myelofibrosis usually shows increased reticulin fibres and fibroblasts whereas 
significant marrow fibrosis is not often seen. However, the finding of BM reticulin 
fibrosis in a SLE patient should not immediately prompt the diagnosis of 
autoimmune myelofibrosis. Mild degrees of reticulin fibrosis can be observed in 
other pathologies such as immune thrombocytopaenia and may be found in many 
patients with SLE when routine BM biopsies are performed (132). Some authors 
conclude that BM biopsy should only be recommended if cytopaenia does not 
recover after conventional therapy [158]. 
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The prognosis of autoimmune myelofibrosis in SLE patients is generally favourable 
and usually responds well to first line treatment [165]. However, in patients who 
eventually do not respond to treatment, transformation to acute leukaemia or other 
complications may occur. 
5.1.4. Treatment 
Glucocorticoids are the first line of treatment and often very successful unlike the 
situation with primary myelofibrosis. Early diagnosis and prompt treatment can lead 
to an improvement in the cytopaenia and in the BM architecture with a resolution of 
the pathology. However, well-established myelofibrosis has a poorer response and 
may be fatal [165].  
In primary myelofibrosis, activating mutations in Janus kinase (JAK) have been 
recognized to play an important part in its pathogenesis [170]. A JAK inhibitor, 
Ruxolitinib, was shown to be effective in the treatment of primary myelofibrosis 
[171-173]. However, these mutations have not been found in immune SLE 
myelofibrosis and Rituxinib has not been used for its treatment as far as we are 
aware. 
IVIg proved to be effective in some patients [165, 174] and there is one case report 
with combined treatment of glucocorticoids and MMF which reports a good 
outcome[175]. 
5.2. Other causes of pancytopaenia 
5.2.1. Secondary macrophage activation syndrome in SLE patients. 
MAS is characterized by increased proliferation and activation of benign 
macrophages and T cells, with increased secretion of proinflammatory 
cytokines[176]. It is classified as primary/familial and secondary/reactive in the 
context of malignancy, systemic autoimmunity, infection, or drug-hypersensitivity 
reaction. 
Secondary MAS is a rare cause of cytopaenia in SLE [176] but may be life-
threatening. Although it is more frequent in paediatric populations, it also can occur 
in adults where it is usually more severe [177]. Given its complex clinical features, 
MAS can be missed in SLE patients [176, 178]. Secondary MAS in SLE patients is often 
present at disease onset. However, it can be triggered by an infection (mostly viral) 
and, sometimes, both flare and infection coexist in SLE patients [179]. 
Its pathogenesis remains unclear. It has been proposed that autoantibodies and 
immune complexes sensitize BM cells to macrophages, which subsequently engage 
in uncontrolled phagocytosis. Moreover, T cell–derived cytokines (IL-1, IL-6, IFN-γ, 
TNF-α) enhance the inappropriate activation of macrophages. This cytokine storm 
might be a result of primary uncontrolled T-cell activation in SLE patients [31]. 
It is often manifested with pancytopaenia associated to hyperferritinaemia, anti-DNA 
antibodies, low C-reactive protein (<30 mg/L), a falling erythrocyte sedimentation 
rate (ESR), hypocomplementaemia and elevated triglycerides. Its clinical 
characteristics include non-remitting high-fever, weight loss, arthritis, pericarditis, 
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rash, myocarditis, nephritis, splenomegaly, hepatomegaly and lymphadenopathy 
[180].   
The therapeutic strategies for MAS in SLE are not well established and to treat this 
syndrome effectively, it is vital to identify the trigger. In SLE patients in which MAS is 
driven by disease activity in the absence of obvious infection, immunosuppressive 
therapy is the main treatment, including high-dose glucocorticoids, CYC or CSA [179, 
181]. When a flare is present along with a concomitant infection, IVIg in addition to 
anti-infective agents should be considered, as well as glucocorticoids [182]. If it is 
triggered by an obvious microbial infection, antibiotics should be initiated and 
immunosuppressive therapy decreased as much as possible. 
6. Evans syndrome. 
Evans syndrome is characterised by the presence of autoimmune haemolytic 
anaemia (AIHA) associated with concomitant or sequential development of 
autoimmune thrombocytopaenia [183]. Therefore, when a SLE patient is diagnosed 
with AIHA a carefully monitoring of the platelet count is mandatory. However, 
secondary Evans syndrome in SLE patients is rare and it often precedes the onset of 
SLE [184]. High-dose glucocorticoids might be used, but once they are stopped or 
tapered, relapses are common. In refractory cases, other drugs used in either AIHA 
or immune SLE thrombocytopaenia have been successfully used, such as danazol 
[185], romiplostim [186] and RTX [187].  
7. Haemostasis alterations 
 
7.1. Thrombosis in SLE patients. 
Thrombosis causes substantial morbidity and mortality in SLE patients. In a 10-year 
prospective cohort study, thrombosis was the second most frequent cause of death 
[188]. Moreover, SLE patients have an increased risk of thrombosis, even in the 
absence of aPL which increases the risk even further [94]. Thrombotic complications 
can be found in > 10% of SLE patients and this risk increases up to 50% in patients 
with lupus anticoagulant [189, 190]. Therefore a risk-stratified approach to 
thrombosis risk factors is required in order to prevent their occurrence. 
The pathogenesis of thrombosis in SLE is multifactorial and several risk factors have 
been identified [191]. Three major conditions have been described historically: 
hypercoagulability, premature atherosclerosis and vasculitis[192]. A hypercoagulable 
state secondary to aPL is the most common mechanism[193]. Other disease-
associated risk factors and predisposing conditions have been reported, e.g. 
hypertension, glucocorticoid treatment, hyperhomocysteinaemia, decreased protein 
S concentration and changes in fibrinolysis [194-196].  
A summary of the main mechanisms involved in the pathogenesis of thrombosis in 
SLE patients can be found in figure 5. 
7.2. Epidemiology and traditional thrombosis risk factors in SLE. 
The age at onset of thrombosis in SLE patients is lower than in the general 
population and its incidence is increased in the first year after diagnosis. This might 
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be related to higher SLE activity during this period, higher levels of circulating 
autoantibodies and immune complexes [197]. Moreover, when focusing on 
cardiovascular thrombotic events, older age at the time of diagnosis and longer 
duration of disease also increase risk for thrombosis [198, 199]. This might be 
explained by the fact that older SLE patients tend to have more accumulated 
damage and more vascular morbidity. 
The role of ethnicity has also been studied. A large prospective study was 
undertaken to determine the incidence and risk factors for arterial and venous 
thromboembolic events in different ethnicity populations [191]. In this study, 625 
patients who fulfilled the ACR criteria for SLE were enrolled (258 Chinese, 140 
African Americans, and 227 Caucasians). The cumulative hazard of arterial events at 
60 months after the diagnosis of SLE was lower in the Caucasians compared to the 
Chinese and African Americans. There was a significantly lower risk of venous 
thrombosis events in the Chinese group when compared with Caucasians. These 
differences could not be fully explained by differences in the prevalence of well-
known risk factors (including age, smoking, diabetes mellitus and hypertension). 
Genetic and immunologic factors may also play a role [191]. 
Smoking is a significant risk factor for vascular events in SLE and has been associated 
with worse outcomes in SLE patients [198, 200]. Hypertension, diabetes mellitus, 
and dyslipidaemia are common in SLE patients and these factors have been 
associated with thrombosis in numerous studies [195, 201]. Given that SLE patients 
have a greater risk of thrombosis than general population, traditional risk factors 
should be assessed regularly and treated appropriately. 
Glucocorticoids, which are commonly used for SLE treatment, are associated with 
thrombosis risk and have also been associated with abnormalities in the coagulation 
cascade when administered in higher doses [202, 203]. 
7.3. SLE, antiphospholipid antibodies and antiphospholipid syndrome. 
aPL  are  associated  with  several  clinical  features notably  venous  and  arterial  
thrombosis, thrombocytopaenia and pregnancy loss. However, aPL may only be 
transiently positive. To be considered significant, they should be persistently positive 
on two occasions, at least 12 weeks apart.  
ACA, lupus anticoagulant and anti-ß2-glycoprotein l (ß2GPI) are well-known risk 
factors for cardiovascular mortality in SLE and are strongly associated with an 
increased incidence of thrombotic events in these patients [204, 205]. For example, 
the presence of lupus anticoagulant has been described as a significant risk factor for 
myocardial infarction [206] and stroke [207]. APS is defined as the presence of at 
least one clinical criteria (vascular thrombosis or pregnancy morbidity) and one 
laboratory criteria (lupus anticoagulant, ACA, anti-β2GPI antibodies) [208]. When 
controlling for other explanatory variables, aPL-positive SLE patients were found to 
have more than three times the odds of having a thrombotic event compared with 
those lacking aPL antibodies [204]. Love et al found that among SLE patients, 42% of 
the lupus anticoagulant-positive and 40% of the aPL-positive patients had a history 
of thrombosis. In contrast, the prevalence of thrombosis in lupus anticoagulant or 
22 
 
ACA negative SLE patients was only 10–18% [190]. Other antibodies to negative-
charged phospholipids (such as phosphatidic acid, phosphatidylinositol and 
phosphatidylserine) have been identified but it remains doubtful whether these are 
actually predictive of thrombosis in SLE patients [209].  
The mechanism by which aPL increase the risk of venous and arterial thrombosis is 
not well understood and several hypothesis have been proposed e.g. they might 
contribute to increased thrombosis by various possible haemostatic mechanisms 
such as: clot formation, inhibition of natural anticoagulant mechanisms and 
impairment of fibrinolysis [210-216]. 
Although they are called anti-phospholipid antibodies, the most important antigen 
identified is the protein co-factor β2GPI [217, 218], aPL can also interact with other 
phospholipid-binding proteins, particularly with prothrombin [216]. This interaction 
may disturb endothelial cell function [219]. Moreover, antiprothrombin antibodies 
have been suggested to possess prothrombinase activity leading to increased fibrin 
production [217].  
aPL react with phospholipid-binding proteins (in particular β2GPI and prothrombin) 
expressed on cell membranes of different cell types, such as monocytes, endothelial 
cells and platelets. The complex binding between aPL and the corresponding cell 
membrane protein leads to cell activation by disturbing the cell membrane and 
promoting signals to the nucleus. Platelet activation (by the anti-β2GPI complex) 
increases the synthesis of thromboxane and the expression of platelet-membrane 
glycoproteins, such as GPIIb/IIIa, which promotes platelet aggregation. Both 
activated monocytes and endothelial cells upregulate the production of tissue factor 
and promote endothelial leukocyte adhesion, cytokine secretion and prostaglandin 
E2 (PGE 2) synthesis [210, 212, 213]. 
aPL might also induce complement activation, which  generates  split  products  that  
then  attract inflammatory  cells  and  initiate  thrombosis  and  tissue  injury [220, 
221]. Increased complement deposition (C1q, C3d and C4d) on platelets has also 
been described in SLE, especially in patients with a previous history of venous 
thrombosis [222, 223]. They also disrupt the fluid phase of coagulation by affecting 
Protein C cleavage system (see Protein C and S section), by disturbing fibrinolysis 
(see Fibrinolysis section) and displacing the binding of the natural anticoagulant 
annexin A5 to anionic structures. 
7.4. Impaired fibrinolysis. 
Impaired fibrinolysis has been reported in patients with SLE and APS. It contributes 
to hypercoagulability and an increased risk of thrombosis. Different mechanisms 
have been described as aetiological agents of impaired fibrinolysis in SLE and APS 
patients. Some are not related to aPL, such as the increased plasminogen activator 
inhibitor type 1 (PAI-1) activity that may inhibit tissue plasminogen activator (tPA) 
activity, while others are related to aPL such β2GPI antibodies, which interferes with 
the interaction of β2GPI with tPA activator and the enhancement of tPA activity 
[224]. 
7.5. Proteins S and C. 
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The protein C system is one of the most important anti-thrombotic pathways 
mediated by the vessel wall. Activated protein C (APC) inhibits thrombin generation 
by cleaving procoagulant protein factors Va and VIIIa, in the presence of protein S 
[225]. Protein S exists in plasma either bound to C4b-binding protein or as a free 
form - the latter being the necessary cofactor for activating Protein C.  In SLE there is 
a reduction of free protein S, despite normal total protein S levels. This may be due 
to increased C4b-binding protein or an increased binding affinity between it and 
protein S [226]. Moreover, aPL may lead to protein C dysfunction by binding to it via 
its β2GPI antigens [227]. 
7.6. Prevention and treatment of thrombosis in SLE patients 
7.6.1. Prevention treatment. 
The use of low dose aspirin as primary thromboprophylaxis has had conflicting 
results. Tektonidou et al reported that treatment duration with aspirin and HCQ is 
associated with decreased thrombosis in aPL-positive patients [228]. Another study 
also reported a lower incidence of thrombosis in APLA-positive patients when given 
ASA prophylaxis [229]. Nevertheless, the Antiphospholipid Antibody Acetylsalicylic 
Acid (APLASA) study found that low dose aspirin was not effective in preventing 
thrombosis in positive aPL patients, when compared to placebo [230]. However, this 
study excluded high-risk groups and has been criticized for being underpowered to 
detect a beneficial effect of aspirin. However, low-dose aspirin is still used as primary 
thromboprophylaxis in patients with SLE and persistently positive aPL antibodies 
[231]. 
HCQ reduces SLE-related morbidity and mortality and it may also reduce thrombotic 
risk [195, 204]. Its antithrombotic potential could be explained by multiple 
mechanisms including: inhibition of platelet aggregation and adhesion [232], 
inhibition of arachidonic acid release from stimulated platelets [233], cholesterol-
lowering [232], blockade of aPL production [234] and inhibition of the 
antiphospholipid-induced receptor (GPIIb/IIIa) expression [235]. Moreover, HCQ 
might decrease thrombus size and time of development in a dose-dependent 
manner [236]. It should be considered in SLE patients who are also positive for aPL, 
in addition to aspirin. 
7.6.2. Thrombosis treatment 
The risk of recurrent thrombosis in positive aPL patients is between 22% and 69% 
[237-239] and this risk increases in the first year after the discontinuation of 
anticoagulation treatment [240, 241]. The duration of tfreatment length depends on 
the presence of aPL, the site of the thrombosis, recurrence and co-existing 
precipitating factors. Prolonged anticoagulation therapy may be necessary. 
Life-long anticoagulation is recommended in APS patients after a thrombotic event. 
This recommendation applies to patients with persistently positive moderate to high 
titres of aPL or with lupus anticoagulant and a definite diagnosis of APS. The target 
international normalized ratio (INR) for APS syndrome patients is 2-3 for venous 
events [242, 243] and 3-4 for arterial or recurrent venous events [244]. Patients with 
thrombosis and aPL positivity who do not fulfil the APS criteria should be managed 
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as the general population. Therefore, patients with venous thromboembolism or 
stroke and a single positive aPL test should be treated with warfarin at a target INR 
of 2.0-3.0 and low-dose aspirin[245]. 
The majority of recurrences occur when INR is sub-therapeutic. Hence INR values 
should be monitored regularly. Moreover, patients with positive lupus anticoagulant 
can have a spurious increase in INR result, which leads to underdosing of vitamin K 
antagonists. If a recurrent event occurred while INR was in therapeutic levels, 
increasing the target INR to higher than 3.0 should be considered, as well as adding 
aspirin or switching to low–molecular-weight heparin (LMWH) [241, 246, 247]. The 
use of direct anticoagulants, namely Rivaroxaban and Apixaban, in patients with APS 
was successful in some case reports [248] but there were also other unsuccessful 
reports with Rivaroxaban [249]. A prospective, randomized controlled phase II/III 
clinical trial of Rivaroxaban in patients with APS (RAPS trial) and previous VTE, with 
or without systemic lupus erythematosus (SLE) has just been completed. It has 
sought to determine whether the intensity of anticoagulation achieved with 
rivaroxaban is not inferior to that of warfarin in these patients [250]. The results 
indicate that Rivaroxaban is not inferior to warfarin [251]. Recently, other designs of 
randomised clinical trials with Apixaban (ASTRO-APS) [252] and Rivaroxaban (TRAPS 
trial) [253] in APS have also been published. 
RTX lead to a significant reduction in aPL among SLE patients [254]. Moreover, a high 
response rate in refractory APS has been described in various case reports and 
series. The clinical resolution of thrombosis and haematologic manifestations was 
reported in the majority of these patients and aPL antibodies levels became negative 
or were significantly reduced [255, 256]. 
8. Conclusion 
Haematological disorders in SLE patients are very diverse and their pathogenesis is 
still not fully understood. They can be a manifestation of SLE itself, a concomitant 
disease or secondary to SLE therapies. The clinical presentation ranges from mild to 
life-threatening. In the mildest presentations, specific targeted treatment is usually 
unnecessary, but, in the most severe cases, immunosuppressive therapy with 
multiple drugs might be lifesaving. However, most evidence is based on case-reports 
or small retrospective studies, with very few randomized controlled trials reported.  
The development of biological therapy in the past 15 years has opened new possible 
ways to treat the most severe cases more effectively but, as in the other 
immunosuppressive drugs, more randomized prospective studies and longer follow-
up periods are necessary to establish their optimal role in treating these 
manifestations.  
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TABLES 
  
Table 1. Red cell alterations in Systemic lupus erythematosus patients. 
 AZA: azathioprine, CYC: cyclophosphamide, GI: gastrointestinal, SLE: systemic lupus erythematosus. 
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Treatment of Autoimmune Haemolytic Anaemia 
Treatment Indications Comments Ref 
GCs First line therapy. 
Initial dose: 1mg/kg/day. 
 
Refractory:  
 After 3 weeks of treatment OR 
 Prednisone >15 mg/day OR 
 >0.1 mg/kg/day of prednisone equivalent for 
maintenance. 
[31] 
AZA To induce remission. 
Steroid-sparing agent. 
Limited evidence in AIHA. [31] 
MMF [257] 
CSA To induce remission in refractory 
cases. 
Discontinuation may be difficult. 
Evidence in refractory AIHA, immune 
thrombocytopaenia and Evans syndrome. 
[258] 
CYC To induce remission in refractory 
cases. 
In a study of high-dose treatment of CYC in AIHA 
refractory patients: 
 All became transfusion independent. 
 2/3 patients went into complete remission (5 
P-AIHA and 1 S-AIHA). 
[259] 
Splenectomy Controversial results.  
Cautious use in DAT-positive AIHA. 
Out of 28 patients with AIHA (21 I-AIHA and 7 S-
AIHA). 
 2 of S-AIHA had a positive response. 
 No criteria to predict response. 
[260] 
30 SLE patients with TTP or AIHA. 
 No difference between splenectomised and 
non-splenectomised. 
[261] 
30 AIHA patients who underwent splenectomy: 
 I-AIHA: effective and safe in refractory 
patients. 
 S-AIHA: increased response to medical 
therapy.  
[262] 
IVIg Possible adjunctive treatment when 
significant toxicity to other drugs. 
Acute benefit in 1/3 AIHA patients. 
Related to good response: 
 Hepatomegaly. 
 Low pre-treatment Hb (6-7g/dl). 
[263] 
Danazol Sporadic use as an addition to first 
line therapy. 
17 patients (10 with warm antibody AIHA, 5 who 
relapsed after initial response to prednisone and 
2 with refractory AIHA): 
 Better responses. 
 Unsuccessful in the relapse group. 
[264] 
Plasma 
exchange 
Use before transfusion of RBC 
without benefits. 
9 patients and total 38 sessions of plasma 
exchange: 
 No significant increase in Hb in patients who 
underwent plasma-exchange before 
transfusion of RBC. 
[265] 
RTX To induce remission in refractory 
cases. 
15 children (9 with AIHA and 6 with Evans 
syndrome). 
 13 patients had >1.5 g/dL increase of Hb and 
>50% reduction in reticulocyte count. 
[266] 
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Table 3. White cell alterations in Systemic lupus erythematosus patients. 
AZA: azathioprine, CYC: cyclophosphamide, GC: glucocorticoids, GI: gastrointestinal, SLE: systemic lupus 
erythematosus. 
 2 non-responder patients had AIHA with 
warm-reactive IgG autoantibodies. 
 DAT positive in 14 children at pre-treatment 
but became negative in 6 after 2 months of 
treatment.  
Other reports in paediatric population. 
 
[267] 
[268] 
Reports in adult population.  [269]  
[270] 
Phase III RCT: 
 Prednisolone and RTX: response increased 
gradually over 6 months.  
 GCs alone: maximum response at 3 months. 
[271] 
Table 2.  Treatment of Autoimmune Haemolytic Anaemia 
AIHA: autoimmune haemolytic anaemia, AZA: azathioprine, CSA: Cyclosporine, CYC: Cyclophosphamide, 
DAT: direct antiglobulin test, GCs: Glucocorticoids, Hb: haemoglobin, I-AIHA: idiopathic autoimmune 
haemolytic anaemia, IVIg: Intravenous Immunoglobulin, MMF: Mycophenolate mofetil, RBC: red blood 
cells, RCT: randomized clinical trial, RTX: Rituximab, Ref: references, S-AIHA: Secondary autoimmune 
haemolytic anaemia, TTP: Thrombotic thrombocytopaenic purpura. 
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Table 4. Platelet alterations in Systemic lupus erythematosus patients. 
AZA: azathioprine, CYC: cyclophosphamide, GI: gastrointestinal, SLE: systemic lupus erythematosus. 
 
Table 5. Systemic lupus erythematosus immune thrombocytopaenia presentation. 
GCs: glucocorticoids, P-ITP: primary immune thrombocytopaenia, SLE: systemic lupus erythematosus. 
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Treatment of Immune Thrombocytopaenia 
Treatment Indications Comments Ref 
GCs 
First line therapy. 
 
 
 Response within 1-8 weeks.  
 High rate of long-term failure. 
 
Oral high-dose dexamethasone 
(40mg/day for 4 days x 4-8 cycles 
with intervals of 2-4 weeks). 
 
Prednisone (tapering from 0,5-
1mg/kg/day) can be used, but 
dexamethasone has similar 
remission rates and better long-term 
responses. 
 
Pulse methylprednisolone has an 
increased risk of serious adverse 
effects (mainly avascular necrosis) 
without added benefits when 
compared to high-dose oral GCs. 
[114]  
 
[115]  
 
[116] 
Danazol 
In combination with GCs when refractory 
to first line therapy.  
 
Steroid-sparing agent. 
 
Variable dosing between studies. 
[116]  
[272] 
[273] 
16 patients: 
 Initially treated with 200 mg/day 
and then increased by 200 mg 
every four weeks until response.  
 All patients had a good response 
within two months. 
 In an average follow-up of 18.2 
months, danazol was tapered 
down to 200/400 mg/day 
without recurrence. 
[185] 
6 patients refractory to GCs were 
successfully treated with: 
 High initial dose (800 mg/day for 
8 weeks). 
 Lower maintenance dose 
(ranging from 200 to 600 
mg/day).  
Danazol could not be discontinued 
without recurrence. 
[274] 
 Danazol is safe and well 
tolerated. 
 It may be used during pregnancy. 
[275] 
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HCQ 
 Increased rate of sustained 
response. 
[116] 
CYC Refractory immune thrombocytopaenia.  
10–15 mg/kg intravenous CYC, 
monthly for at least 4 months: 
 Platelet count increases within 2-
18 weeks. 
 High rates of sustained response.  
 Maintenance therapy rarely 
needed 
[276] 
Concerns about adverse effects led 
to the proposal of new regimen: 
 Induction dose 500 mg, biweekly 
for 3 months. 
 Followed by MMF or AZA, 
improving tolerability without 
loss of efficacy. 
[277] 
MMF 
Refractory immune thrombocytopaenia.  
Steroid-sparing agent. 
Case report of its use as 
maintenance therapy [277]. 
[278] 
[279] 
[280] 
AZA Steroid-sparing agent. 
Case report of its use as 
maintenance therapy [277]. 
[281] 
[282] 
CSA Refractory immune thrombocytopaenia. 
Steroid-sparing agent. 
 Risk of nephrotoxicity 
 Lower doses have been 
successfully used. 
[283] 
[284] 
[285] 
Vincristine 
 Severe side effects: neuropathy 
and bone pain. 
[286] 
IVIg 
Preferred if rapid rise in platelet count is 
necessary due to: 
 Active bleeding. 
 Emergent surgery.  
Initial dose: 400 mg/kg daily for 5 
consecutive days. 
Maintenance: 400 mg/kg monthly in 
an 
intermittent or continuous manner.  
 
Not enough evidence analysing long-
lasting response.  
[287] 
[288] 
[289] 
[290] 
[291] 
[292]  
Splenectomy Refractory immune thrombocytopaenia.  
Good short term response in SLE 
patients.  
[117, 
293] 
[118] 
[294]  
Controversial results in long-term response 
when compared with P-ITP. 
Lack of follow-up in studies 
Less durable response.  [119] 
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In a cohort 17 splenectomised 
patients sustained response was 
found in 65%, with a mean of 65 
months of follow-up (ranging from 3 
to 209 months). 
[116] 
Controversial results in infection risk 
Increased risk of infection due to: 
 Streptococcus pneumoniae. 
 Neisseria meningitides. 
 Haemophilus influenzae  
 
Vaccination with anti-pneumococcal, 
Haemophilus influenza type B, 
meningitis C and Influenza. 
 
Prophylactic antibiotics, particularly 
in concomitant chronic 
hypocomplementaemia.  
[120] 
[261] 
9 SLE splenectomised patients 
without increased risk of infection 
(mean follow-up of 93 months). 
[295] 
RTX Refractory immune thrombocytopaenia. 
Significantly decreases antiplatelet 
antibodies, especially IgG isotype.  
  
Preferred to splenectomy because it 
is beneficial for other manifestations 
of SLE. 
 
Case report evidence of its success. 
[122] 
[296] 
[297] 
[298] 
[299] 
[300] 
[301]  
IL-11 
Life-threatening refractory immune 
thrombocytopaenia  
Case report of a patient with 
intrabronchial haemorrhage 
refractory to IVIg, high-dose GCS, 
CYC and plasma exchange. 
Response to IL-11 over a 5-day 
period, achieving a platelet count of 
50x109/mm3 
[302] 
Eltrombopag Refractory immune thrombocytopaenia. 
Steroid-sparing agent. 
Thrombopoeitin receptor agonists. 
Increase platelet production. 
[303]  
Romiplostim [304] 
Table 6. Treatment of Immune Thrombocytopaenia. 
AZA: azathioprine, CSA: Cyclosporine, CYC: Cyclophosphamide, GCs: Glucocorticoids, HCQ: 
Hydroxychloroquine, IVIg: Intravenous immunoglobulin, SLE: Systemic lupus erythematosus. 
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FIGURES 
 
Figure 1 Chronic disease anaemia pathogenesis. 
Righ corner: Hepcidin role in chronic disease anaemia.Left corner: Cytokin role in chronic disease anaemia. 
Red lines indicate inhibition and green lines indicate stimulation. 
BM: bone marrow, DMT1: divalent metal transporter 1, EPO: erythropoietin, Fe 2+: iron, FPN: ferroportin, 
IEPC: intersticial epo producting cells, IFN γ: interferon γ, IL1: interleukin 1, IL6: interleukin 6, IL10: interleukin 
10, Tf: transferrin, TNF α: tumour necrosis factor α, sTfR: soluble transferrin receptor. 
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Figure 2. Differential diagnose of systemic lupus erythematosus anaemias: iron deficiency anaemia and 
chronic disease anaemia. 
sTfR: soluble transferrin receptor. 
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Figure 3. Systemic lupus erythematosus immune thrombocytopaenia pathogenesis. A summary of 
autoantibodies interactions in bone marrow, peripheral blood and spleen.  
a- β2GPI ab: anti β2 glycoprotein I antibody, a-c-Mpl ab: anti thrombopoietin receptor antibody, a- GPIaIIa ab: 
anti glycoprotein IaIIa antibody, a-GPIbIX ab: anti glycoprotein IbIX antibody, a-GPIIbIIIa ab: anti glycoprotein 
IIbIIIa antibody, a-TPO ab: anti thrombopoietin antibody, β2GPI: β2 glycoprotein I, c-Mpl: thrombopoietin 
receptor, Fc-γ r: fragment, crystallisable γ receptor,  GPIaIIa: glycoprotein IaIIa, GPIbIX: glycoprotein IbIX, 
GPIIbIIIa: glycoprotein IIbIIIa, IFN γ: interferon γ, IL-3: interleukin 3, IL-6: interleukin 6, IL-11: interleukin 11, LIF: 
leukemia inhibitory factor, M-CFU: Megakaryocytic colony forming units, MCPH: Macrophage, NF-E2: 
transcription factor NF-E2 45 kDa subunit, TNF α: tumour necrosis factor α, TPO: thrombopoietin. 
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Figure 4. Systemic lupus erythematosus immune thrombocytopaenia: treatments and targets. 
Ab: autoantibodies, AZA: azathioprine, CSA: cyclosporine, CYC: cyclosphosphamide, GCS: glucocorticoids, M-
CFU: Megakaryocytic colony forming units, MCPH: Macrophage. 
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Figure 5. Main mechanisms in the pathogenesis of thrombosis in systemic lupus erythematosus patients. 
1. Interaction of antiphospholipid antibodies with cell membranes of monocytes, endothelial cells 
and platelets. 
2. Alterations in the coagulation cascade. 
3. Impairment of fibrinolysis and interaction with protein S and protein C. 
4. Complement system role. 
 
A5: annexin A5, APC: activated protein C, aPL: antiphospholipid antibody, β2GPI: β2 glycoprotein I, C4b-BP: 
C4b-binding protein, CK: cytokines , CL-Fb: cross linked fibrin, EC: endothelial cell, GPIIb/IIIa: glycoprotein 
IIb/IIIa, LK: leukocyte, MC: monocyte, PAI: plasminogen activator inhibitor type 1 PC: protein C, PGE2: 
prostaglandin E2, PS: protein S,  PT: prothrombin antigen, tF: tissue factor, tFPI: tissue factor pathway 
inhibitor, tPA: tissue plasminogen activator, TXA2: Thromboxane A2. 
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